Renaissance Capital logo

MIST News

Heart rate condition biotech Milestone Pharmaceuticals prices upsized IPO at $15 midpoint

Milestone Pharmaceuticals logo

Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, raised $83 million by offering 5.5 million shares at $15, selling an additional 500,000 shares at the midpoint of the range of $14 to $16.  Milestone...read more

US IPO Week Ahead: It's Uber uber alles with biggest IPO in 5 years

UBER

If 2019 is indeed the "year of Uber," then the week ahead can only be the "week of Uber." After years of IPO speculation, Uber (UBER) is expected to raise $8.5 billion at the $47 midpoint, with insiders selling $1.3 billion in the...read more

Heart rate condition biotech Milestone Pharmaceuticals sets terms for $75 million IPO

Milestone Pharmaceuticals logo

Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, announced terms for its IPO on Monday. The Montreal, Canada-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At...read more

Heart rate condition biotech Milestone Pharmaceuticals files for a $86 million IPO

Milestone Pharmaceuticals logo

Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Montreal, Canada-based company was founded in 2003 and plans to list on...read more

Archived Headlines